TRANSGENOMIC WAVE NUCLEIC ACID HIGH SENSITIVITY FRAGMENT ANALYSIS: BRAIN CANCER

转基因波核酸高灵敏度片段分析：脑癌

• 批准号: 7335246
• 负责人: ROBERT J DISTEL
• 金额: $ 4.92万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-15 至 2007-03-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7335246
• 关键词: brain neoplasms; clinical trials; gel; gene mutation; neoplasm /cancer; nucleic acids

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): The purpose of this application is to request NCCR SIG funding for a Transgenomic Wave dHPLC system for the newly formed Translational Research Laboratory in the Center for Clinical and Translational Research at the Dana-Farber Cancer Institute. This system will establish an essential platform for screening and detection of known and unknown mutations in archival and ongoing clinical trial patient tissue samples. The grant describes the capabilities of the Transgenomic Wave System and how the instrument would enhance the overall quality and efficiency of clinical and translational researchers' investigations and lead to tangible reduction in the suffering caused by the cancer scourge. The Translational Research Laboratory has as its mandate through the strategic plan of the DFCI to improve clinical trial science by providing clinical investigators with an interdisciplinary forum to share research ideas and issues, collaborative technical and scientific expertise, access to the latest technology, and resources to develop and validate new technologies to analyze relevant biological markers, surrogates and drug targets in patients. We have found the Transgenomic WAVE(r) System to be the most sensitive and accurate technology available for detection of genetic mutations and polymorphisms, and unlike gel-based systems the WAVE systems are fully automated, robust, versatile and cost effective. The WAVE System is more sensitive, faster and less expensive to operate than automated DNA sequencing or any of the traditional gel-based techniques, such as SSCP, TDGS, etc. Efficiency is increased and costs reduced because greater sensitivity allows for multiplexing and screening by dHPLC, and allows us to sequence only those samples that contain a mutation or SNP. The acquisition of this machine will help our clinicians/researchers narrow the gap between the great advances in the development of targeted drugs for cancer and our understanding of how, when, and who these drugs will help. A case in point is the development of epidermal growth factor receptor inhibitors. The remarkable benefits of these drugs in treating lung cancer were only fully understood and the use of the drug defined with an understanding that efficacy hinged on the presence of somatic mutations in the EGFR gene.

该子项目是利用 NIH/NCRR 资助的共享仪器补助金提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是资助机构，不一定是研究者的机构。描述（由申请人提供）：本申请的目的是请求 NCCR SIG 资助用于丹纳法伯癌症研究所临床和转化研究中心新成立的转化研究实验室的 Transgenomic Wave dHPLC 系统。该系统将建立一个重要的平台，用于筛选和检测档案和正在进行的临床试验患者组织样本中的已知和未知突变。该赠款描述了跨基因组波系统的功能，以及该仪器如何提高临床和转化研究人员研究的整体质量和效率，并切实减少癌症祸害造成的痛苦。 转化研究实验室的任务是通过 DFCI 的战略计划来改进临床试验科学，为临床研究人员提供一个跨学科论坛来分享研究想法和问题、协作技术和科学专业知识、获取最新技术和资源开发和验证新技术来分析患者的相关生物标志物、替代物和药物靶点。 我们发现 Transgenomic WAVE(r) 系统是可用于检测基因突变和多态性的最灵敏、最准确的技术，与基于凝胶的系统不同，WAVE 系统是完全自动化、稳健、多功能且具有成本效益的。与自动 DNA 测序或任何传统的基于凝胶的技术（例如 SSCP、TDGS 等）相比，WAVE 系统更灵敏、更快且操作成本更低。由于更高的灵敏度允许通过以下方式进行多重分析和筛选，因此提高了效率并降低了成本dHPLC，使我们能够仅对那些包含突变或 SNP 的样本进行测序。购买这台机器将帮助我们的临床医生/研究人员缩小癌症靶向药物开发的巨大进步与我们对这些药物如何、何时以及谁将发挥作用的理解之间的差距。表皮生长因子受体抑制剂的开发就是一个典型的例子。这些药物在治疗肺癌方面的显着益处才被充分理解，并且在认识到疗效取决于 EGFR 基因中体细胞突变的存在的情况下才定义药物的使用。